喘中的免疫学表型及其对长期结局的影响
Wang Chung Kwok1, Terence Chi Chun Tam1, James Chung Man Ho1
1Division of Respiratory Medicine, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
喘患者,特别是非酸性表型患者,在5年内面临更高的功能下降和慢性病进展的风险. 这凸显了在喘管理中监测脏健康的重要性.
科学领域:
- 肺部病理学 肺部病理学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
背景情况:
- 喘与全身炎症和非呼吸系统问题有关.
- 喘患者的长期结局没有得到充分的记录.
- 了解喘表型对脏健康的影响至关重要.
研究的目的:
- 调查喘表型 (eosinophilic 与非eosinophilic) 与长期结局之间的关系.
- 评估喘患者病进展的风险,血中异蛋白细胞数量有所变化.
- 评估喘对慢性病 (CKD) 进展的影响.
主要方法:
- 对504名患有1-3期CKD的喘患者进行前性评估.
- 根据血液中埃索诺菲尔数 (BEC) 的数据,将喘分为埃索诺菲尔 (≥300细胞/毫米3) 和非埃索诺菲尔 (<300细胞/毫米3) 现象型.
- 在5年内评估结局,包括进展和估计的球过率 (eGFR) 降低.
主要成果:
- 104名患者 (20.6%) 经历了性进展.
- 与异酸性喘患者相比,非异酸性喘患者的进展风险显著增加 (aOR为2.615) 和eGFR下降速度更快 (-4.29mL/min/1.73m2/年).
- 性进展与死亡风险增加有关 (aHR 1.614).
结论:
- 慢性功能恶化在喘患者中很常见.
- 非酸性喘表型是病进展的重要危险因素.
- 对喘患者来说,监测功能是必不可少的,特别是那些具有非eosinophilic表型的患者.
更多相关视频
09:58A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
08:44Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
Published on: May 30, 2020
相关概念视频
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-I: Introduction
